Clinical-stage Biopharmaceutical Company Granted Major European Patent
Clinical-stage Biopharmaceutical Company Granted Major European Patent
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use.
Disclaimer: This article is for informational purposes only and should not be construed as investment or medical advice. Always consult with a qualified professional before making any business or healthcare decisions.
Real-time information is available daily at https://stockregion.net
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company dedicated to developing innovative ocular therapies, has recently announced the grant of a significant European patent. This patent, titled “Compositions Comprising Chemerin Analogs and Methods of Use,” covers the company's novel OK-101 chemerin analogs. This development marks a crucial milestone for OKYO Pharma as it strengthens its intellectual property portfolio in the treatment of inflammatory dry eye disease (DED) and other anterior ocular segment diseases, including neuropathic corneal pain (NCP).
The European Patent
The new European patent, which lists Raj Patil, Chief Scientific Officer of OKYO Pharma, as a joint inventor, focuses on the use of OK-101 chemerin analogs. These analogs are designed to treat a variety of diseases and conditions, particularly those related to ocular inflammation and pain. The grant of this patent presents the innovative nature of OKYO Pharma's research and its commitment to addressing unmet medical needs in ocular health.
Dr. Gary S. Jacob, Ph.D., CEO of OKYO Pharma, expressed his excitement about the patent issuance, stating that it reinforces the company's position in developing groundbreaking therapies for ocular conditions. He emphasized that the patent not only fortifies OKYO Pharma’s intellectual property but also paves the way for further advancements in their pipeline of treatments aimed at improving patient outcomes for those suffering from ocular pain and inflammation. OK-101 is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor. This receptor is typically found on immune cells within the eye that are responsible for the inflammatory response. The development of OK-101 leverages membrane-anchored-peptide technology to create a long-acting drug candidate specifically aimed at treating dry eye disease.
The primary therapeutic action of OK-101 is its ability to produce anti-inflammatory and pain-reducing effects. In preclinical studies involving mouse models, OK-101 has demonstrated efficacy in reducing symptoms associated with dry eye disease and neuropathic corneal pain. The lipid anchor incorporated into the drug molecule is designed to combat washout, thereby enhancing the residence time of OK-101 within the ocular environment. This prolonged residence time is expected to improve the drug's effectiveness in treating ocular conditions.
Clinical Progress
Recently, OK-101 showed statistical significance in multiple endpoints during a Phase 2, multi-center, double-blind, placebo-controlled trial focused on treating DED. This promising outcome has set the stage for further clinical trials, including an upcoming Phase 2 trial aimed at evaluating the efficacy of OK-101 in treating neuropathic corneal pain in patients experiencing this debilitating condition.
OKYO Pharma Limited is a clinical-stage biopharmaceutical company that trades on the NASDAQ Capital Market under the symbol OKYO. The company's focus is on discovering and developing novel molecules to treat inflammatory DED and ocular pain. With a strong commitment to innovation and patient care, OKYO Pharma is actively engaged in advancing its therapeutic pipeline to address unmet medical needs in ocular health. Dr. Gary S. Jacob highlighted the company’s ongoing efforts to explore strategic partnerships and collaborations. Such alliances are crucial for accelerating the development and commercialization of OKYO Pharma’s pipeline candidates. By partnering with other organizations, OKYO aims to leverage additional expertise and resources, thereby enhancing the potential for bringing effective therapies to market.
In line with its strategic vision, OKYO Pharma has recently completed a Phase 2 trial for OK-101 targeting dry eye disease. The company is now preparing to initiate another Phase 2 trial to investigate the potential of OK-101 in treating neuropathic corneal pain. These developments reflect OKYO Pharma’s dedication to advancing its clinical programs and delivering innovative treatments for ocular conditions.
The grant of the European patent for OK-101 chemerin analogs marks a pivotal moment for OKYO Pharma. It not only validates the company’s scientific approach but also positions OKYO for continued growth and success in the biopharmaceutical industry. As OKYO Pharma progresses with its clinical trials and explores new therapeutic avenues, the company remains steadfast in its mission to improve the quality of life for patients suffering from ocular diseases.
Disclaimer: The information provided in this article is intended for informational purposes only and should not be construed as investment or medical advice. Consult with a qualified professional before making any decisions based on this information.
Real-time information is available daily at https://stockregion.net